KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Asset Writedowns and Impairment (2016 - 2025)

Elevance Health (ELV) has disclosed Asset Writedowns and Impairment for 15 consecutive years, with $38.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $38.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.0 million, a 43.75% decrease, with the full-year FY2025 number at $108.0 million, up 4.85% from a year prior.
  • Asset Writedowns and Impairment was $38.0 million for Q4 2025 at Elevance Health, up from $7.0 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $73.0 million in Q4 2021 to a low of $7.0 million in Q4 2022.
  • A 3-year average of $39.3 million and a median of $38.0 million in 2025 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 2333.33% in 2021, then tumbled 90.41% in 2022.
  • Elevance Health's Asset Writedowns and Impairment stood at $73.0 million in 2021, then crashed by 90.41% to $7.0 million in 2022, then skyrocketed by 442.86% to $38.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELV's Asset Writedowns and Impairment are $38.0 million (Q4 2025), $7.0 million (Q4 2022), and $73.0 million (Q4 2021).